Nobasite, 250 mg 20 pcs.

Pharmacotherapeutic group: antiviral drug.

ATX code: J05AX

Pharmacological properties

Pharmacodynamics

Enisamy iodide is an antiviral agent derived from isonicotinic acid. It effectively suppresses action of influenza viruses and other pathogens of acute respiratory viral infections (ARI) due to the direct (inhibitory) influence on the process of virus penetration through the cell membrane.

It has interferonogenic properties and increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in the blood plasma by 3-4 times.

Enhances resistance of the body to viral infections.

Limits acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.

Pharmacokinetics

After oral administration enisamide iodide quickly enters the blood, its maximum concentration in the blood is observed 2-2.5 hours after consumption. The elimination half-life is 13.5-14 hours, metabolized in the liver, but rapidly eliminated from the tissues (elimination half-life is 2-3 hours). It is excreted 90-95% in the urine as metabolites.

Indications

Treatment of influenza and other acute respiratory viral infections in adults and adolescents, including as part of complex therapy.

Pharmacological effect

Pharmacotherapeutic group: antiviral agent.

ATX code: J05AX

Pharmacological properties

Pharmacodynamics

Enisamia iodide is an antiviral agent derived from isonicotinic acid. Effectively suppresses the effect of influenza viruses and other pathogens of acute respiratory viral infections (ARVI) due to the direct (inhibitory) effect on the process of penetration of viruses through the cell membrane.

It has interferonogenic properties, helps increase the concentration of endogenous interferon (interferon alpha and interferon gamma) in the blood plasma by 3-4 times.

Increases the body’s resistance to viral infections.

Reduces acute clinical manifestations of viral intoxication and helps reduce the duration of the disease.

Pharmacokinetics

After ingestion, enisamium iodide quickly enters the blood; its maximum concentration in the blood is observed 2-2.5 hours after consumption. The half-life is 13.5-14 hours, metabolized in the liver, but quickly eliminated from tissues (half-life is 2-3 hours). 90–95% is excreted from the body in the form of metabolites.

Special instructions

The drug should be prescribed with caution to patients with thyroid diseases, especially hyperthyroidism.

Impact on the ability to drive vehicles and machinery

Taking enisamium iodide does not affect the ability to drive vehicles or operate machinery.

Active ingredient

Enisamia iodide

Composition

1 tablet contains:

core:

active ingredient:

N-methyl-4-benzylcarbamidopyridinium iodide (enisamium iodide) (calculated as a 100% anhydrous substance) – 125.0 mg/250.0 mg.

excipients:

lactose monohydrate – 33.4 mg/66.8 mg,

microcrystalline cellulose 101 – 10.0 mg/20.0 mg,

sucrose (sugar) – 9.0 mg/18.0 mg,

povidone K-17 (Plasdon K-17) – 3.6 mg/7.2 mg,

copovidone (Plasdon S-630) – 1.4 mg/2.8 mg,

crospovidone (Polyplasdon XL-10) – 3.8 mg / 7.6 mg,

talc – 1.9 mg/3.8 mg,

calcium stearate – 1.9 mg/3.8 mg.

film shell:

Aquarius Prime BAN314047 Yellow – 6 mg/12 mg (hypromellose – 3.96 mg/7.92 mg, titanium dioxide – 1.3437 mg/2.6874 mg, caprylic/caprylate (caprylic/capric triglyceride) –
0.54 mg/1.08 mg, yellow iron oxide dye – 0.042 mg/0.084 mg, red iron oxide dye – 0.0003 mg/0.0006 mg, quinoline yellow dye – 0.114 mg/0.228 mg).

Pregnancy

Use is contraindicated during pregnancy and breastfeeding.

Contraindications

Hypersensitivity to any of the components of the drug.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Sucrase/isomaltase deficiency, fructose intolerance.

Children under 12 years of age, pregnancy, breastfeeding period.

The presence of allergic reactions, regardless of the nature of the allergen in the anamnesis.

Severe organic damage to the liver and kidneys.

With caution

Patients with thyroid diseases, especially hyperthyroidism.

Side Effects

Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, itching.

From the gastrointestinal tract: dryness and bitter taste in the mouth, swelling of the oral mucosa, hypersalivation, yellow tongue, nausea, vomiting, heartburn, abdominal pain, heaviness in the right hypochondrium, diarrhea, bloating.

From the respiratory system: shortness of breath, throat irritation.

In the post-registration period, the following adverse reactions were observed in isolated cases: headache, dizziness, weakness, fluctuations in blood pressure.

If you experience the side effects listed in the instructions, or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Interactions with other drugs have not been sufficiently studied.

The drug NOBASIT®
enhances the effect of antibacterial and immunomodulatory agents. It is advisable to combine this drug with ascorbic acid and other vitamins. Also, the drug NOBASIT® can be prescribed simultaneously with the use of recombinant interferon.

If you are using the above or other medications (including over-the-counter medications) before using NOBASIT®
consult your doctor.

Overdose

In case of an overdose of the drug, the side effects described in the corresponding section may increase. When they appear, gastric lavage and symptomatic treatment are performed.

Storage conditions

Store the blister pack or jar in a pack at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiration date stated on the package.

Manufacturer

Irbitsky Chemical Plant, Russia